The agreement brings together Imugene’s oncolytic virus CF33-CD19 (onCARlytics) and JW’s CD19-directed autologous CAR-T therapy, Carteyva, in a program that spans preclinical studies through to a Phase 1 investigator-initiated clinical trial in China. …
Imugene and JW Therapeutics join forces on first-in-class combination for solid tumours
November 27, 2025 Australian Biotech
Latest Video
New Stories
-
Landmark rorkforce report warns Australia’s hospital pharmacy system is at an 'inflection point'
November 27, 2025 - -
Australia releases first national estimate of women living with metastatic breast cancer
November 27, 2025 - - Latest News -
Imugene and JW Therapeutics join forces on first-in-class combination for solid tumours
November 27, 2025 - - Australian Biotech -
Algorae Pharmaceuticals secures new supply of chemotherapy for Australia through Dr Reddy’s partnership
November 27, 2025 - - Latest News -
An interview that reminds us of the missing discussion in Australia
November 27, 2025 - - Latest News -
Neurizon Therapeutics entering 'a promising new horizon” as ALS program advances
November 26, 2025 - - Australian Biotech -
Slade Pharmacy marks anniversary with record research contributions at conferences
November 26, 2025 - - Latest News